Patents Examined by Mina Haghighatian
  • Core stabilized microcapsules, method of their preparation and uses thereof
    Patent number: 10653899
    Abstract: The present invention provides core-stabilized microcapsules, wherein said core comprises at least one active agent encapsulated within an inorganic oxide shell, processes for their preparations, comparisons comprising them and uses thereof.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: May 19, 2020
    Assignee: SOL-GEL TECHNOLOGIES LTD.
    Inventors: Ofer Toledano, Haim Bar-Simantov, Hanan Sertchook, Sharon Fireman-Shoresh, Dorit Marco
  • Inhalable formulation
    Patent number: 10653704
    Abstract: This invention provides a process for preparing an inhalable active pharmaceutical ingredient comprising the steps of heating a suspension of an active pharmaceutical ingredient in a liquefied propellant in a vessel, evaporating the propellant and collecting the resultant powder.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: May 19, 2020
    Assignee: Teva Branded Pharmaceutical Products R&D, Inc.
    Inventors: Mukul Dalvi, Jacquelyn McCabe
  • Pyrimidinyloxy benzene derivatives as herbicides
    Patent number: 10654840
    Abstract: Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, wherein Q, Z, R2, R3 and m are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound or a composition of the invention.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: May 19, 2020
    Assignee: FMC Corporation
    Inventors: Nicholas Ryan Deprez, Ravisekhara Pochimireddy Reddy, Paula Louise Sharpe, Thomas Martin Stevenson
  • High-strength testosterone undecanoate compositions
    Patent number: 10653706
    Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: May 19, 2020
    Assignee: Lipocine Inc.
    Inventors: Chandrashekar Giliyar, Basawaraj Chickmath, Nachiappan Chidambaram, Mahesh V. Patel, Srinivansan Venkateshwaran
  • Compositions and methods for ophthalmic and/or other applications
    Patent number: 10646436
    Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: May 12, 2020
    Assignee: The Johns Hopkins University
    Inventors: Alexey Popov, Elizabeth M. Enlow, Hongming Chen, James Bourassa
  • Compositions and methods for ophthalmic and/or other applications
    Patent number: 10646437
    Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: May 12, 2020
    Assignee: The Johns Hopkins University
    Inventors: Alexey Popov, Elizabeth M. Enlow, Hongming Chen, James Bourassa
  • Reduction treatment agent, reduction cosmetic, reduction food and method for producing reduction treatment agent
    Patent number: 10639249
    Abstract: A reduction treatment agent made of a powder with a particle size within a range of 1500 to 3000 mesh, the powder containing: 20 to 40 parts of a mixed-oxide powder containing magnesium oxide and zinc oxide; and 60 to 80 parts of an organic acid powder containing calcium, ascorbic acid, citric acid and salt. The reduction treatment agent may further contain one to six kinds of metal powder selected from the group of copper, molybdenum, nickel, cobalt, iron and aluminum, each in an amount of one part. Due to this configuration, the reduction treatment agent can be easily mixed with various substances when added to those substances. Even if the target substance is not water, the agent can entirely and uniformly change that substance into a reduced state. Additionally, the reduction treatment agent can act as a surfactant, and therefore, can be used as cosmetics or food.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: May 5, 2020
    Inventors: Eiko Kinoshita, Tatehiko Ogawa, Irene Fan
  • Stable pressurized aerosol solution composition of glycopyrronium bromide and formoterol combination
    Patent number: 10617638
    Abstract: Aerosol solution compositions intended for use with a pressurized metered dose inhaler, comprising glycopyrronium bromide and formoterol, or a salt thereof or a solvate of said salt, optionally in combination with one or more additional active ingredients, and stabilized by a selected amount of a mineral acid, exhibit improved stability when contained in a can internally coated by a resin comprising a fluorinated ethylene propylene (FEP) polymer.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: April 14, 2020
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Sauro Bonelli, Diego Copelli, Massimiliano Dagli Alberi, Francesca Usberti, Enrico Zambelli
  • Stable pressurized aerosol solution composition of glycopyrronium bromide and formoterol combination
    Patent number: 10617669
    Abstract: Aerosol solution compositions intended for use with a pressurized metered dose inhaler, comprising glycopyrronium bromide and formoterol, or a salt thereof, optionally in combination with one or more additional active ingredients, and stabilized by a selected amount of a mineral acid, exhibit improved stability when contained in an aerosol can provided with a metering valve having at least a butyl rubber gasket.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: April 14, 2020
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Sauro Bonelli, Diego Copelli, Massimiliano Dagli Alberi, Francesca Usberti, Enrico Zambelli
  • Dimethyl sulfoxide (DMSO) or DMSO and methylsulfonylmethane (MSM) formulations to treat infectious diseases
    Patent number: 10596109
    Abstract: Embodiments of the invention relate generally to formulations comprising dimethylsulfoxide (DMSO) alone or in combination with methylsulfonylmethane (MSM), and one or more therapeutic agents, and uses of such formulations to treat infectious diseases. In several embodiments, such formulations are effective in treating drug-resistant infectious diseases, for example, drug-resistant tuberculosis.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: March 24, 2020
    Assignee: Abela Pharmaceuticals, Inc.
    Inventors: Colette Cozean, Rodney Benjamin, Anthony Keller, Jeff Varelman
  • Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
    Patent number: 10596149
    Abstract: Aerosol solution compositions intended for use with a pressurized metered dose inhaler, comprising glycopyrronium bromide and formoterol, or a salt thereof, optionally in combination with one or more additional active ingredients, and stabilized by a selected amount of a mineral acid, exhibit improved stability when contained in an aerosol can provided with a metering valve having at least a butyl rubber gasket.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: March 24, 2020
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Sauro Bonelli, Diego Copelli, Massimiliano Dagli Alberi, Francesca Usberti, Enrico Zambelli
  • Post-emergence herbicide
    Patent number: 10595534
    Abstract: Some embodiments relate to herbicide compositions and methods of inducing phyotoxicity in a plant, by administering an aqueous composition to foliar portions of the plant. This aqueous composition includes at least one nutrient, and at least one adjuvant, and has a pH of about 4 to about 7. In some embodiments, the aqueous composition comprises an organic or mineral acid. In some embodiments, the phytotoxicity is topical. In some embodiments, the phytoxicity is systemic. Without being limited by theory, the nutrient is absorbed by the plant in excess, thereby killing the plant.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: March 24, 2020
    Assignee: Belvedere Foliar LLC
    Inventor: David A. Cobb
  • Stable pressurized aerosol solution composition of glycopyrronium bromide and formoterol combination
    Patent number: 10596113
    Abstract: Aerosol solution compositions intended for use with a pressurized metered dose inhaler, comprising glycopyrronium bromide and formoterol, or a salt thereof or a solvate of said salt, optionally in combination with one or more additional active ingredients, and stabilized by a selected amount of a mineral acid, exhibit improved stability when contained in a can internally coated by a resin comprising a fluorinated ethylene propylene (FEP) polymer.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: March 24, 2020
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Sauro Bonelli, Diego Copelli, Massimiliano Dagli Alberi, Francesca Usberti, Enrico Zambelli
  • Organic nasal treatment solution
    Patent number: 10596105
    Abstract: A nasal spray or therapy solution is provided having organic glycerin; an organic preservative system containing glycerin, citrus reticulata fruit extract, citrus aurantium amara fruit extract, citrus aurantium sinensis peel extract, ascorbic acid, citric acid, lactic acid, water; sodium chloride; water; whereby said nasal spray exhibits inhibited bacteriological growth in vitro for up to 36 months.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: March 24, 2020
    Inventors: Max Spielberg, David Johnson
  • Picolinamide compounds with fungicidal activity
    Patent number: 10588318
    Abstract: This disclosure relates to picolinamides of Formula I and their use as fungicides.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: March 17, 2020
    Assignee: Dow AgroSciences LLC
    Inventors: Karla Bravo-Altamirano, Yu Lu, Brian A. Loy, Zachary A. Buchan, David M. Jones, Jeremy Wilmot, Jared W. Rigoli, Kyle A. Dekorver, John F. Daeuble, Sr., Jessica Herrick, Xuelin Wang, Chenglin Yao, Kevin G. Meyer
  • Transdermal formulation for the treatment of pain and/or inflammation
    Patent number: 10588871
    Abstract: Described herein are transdermal formulations of phytocannabinoids and methods of using the same in the treatment of pain and/or inflammation.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: March 17, 2020
    Assignee: NEXZOL PHARMA, INC.
    Inventors: Joseph M. Fracassi, Thomas J. Scarlata
  • Compositions containing cyclodextrin-based metal organic frameworks
    Patent number: 10583147
    Abstract: This disclosure relates to a composition that includes an active agent and a porous cyclodextrin-based metal organic framework (CD-MOF). The CD-MOF includes at least a metal cation and a plurality of cyclodextrin molecules. The composition includes from about 0.05 mg to about 0.5 mg of the active agent per 1 mg of the CD-MOF. Methods of preparing and using the compositions are also disclosed.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: March 10, 2020
    Assignee: PanaceaNano, Inc.
    Inventors: Benjie N. Limketkai, Youssry Y. Botros
  • Method for treating a degenerative disease of the nervous system using 3-methoxy-pregnenolone or derivatives thereof
    Patent number: 10561671
    Abstract: The present invention relates to a method of enhancing retention of recognition memory and/or recovering recognition memory deficits using 3?-methoxy-pregna-5-ene-20-one.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: February 18, 2020
    Assignee: MAPREG
    Inventors: Etienne-Emile Baulieu, Esther Fellous, Paul Robel
  • Method of making particles for use in a pharmaceutical composition
    Patent number: 10561613
    Abstract: A method for making composite excipient particles for use in a pharmaceutical composition comprises a milling step in which particles of an excipient material are milled in the presence of an additive material. The product particles are of small size and the milling requires relatively low input of time and energy. The composite particles are suitable for use in inhalable pharmaceutical compositions.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: February 18, 2020
    Assignee: VECTURA LIMITED
    Inventors: John Nicholas Staniforth, David Alexander Vodden Morton, Rossella Musa
  • N-(1,3,4-oxadiazol-2-yl)aryl carboxamide derivatives with herbicidal action
    Patent number: 10556874
    Abstract: N-(1,3,4-Oxadiazol-2-yl)arylcarboxamide derivatives of the general formula (I) are described as herbicides. In this formula (I), V, X and Z represent radicals such as hydrogen, organic radicals such as alkyl, and other radicals such as halogen. A represents an oxadiazole radical. W is CY or N.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: February 11, 2020
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventors: Arnim Koehn, Christian Waldraff, Hartmut Ahrens, Ines Heinemann, Ralf Braun, Hansjoerg Dietrich, Christopher Hugh Rosinger, Elmar Gatzweiler